EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014

Ultra-sensitive and highly-specific cancer mutation detection

EKF Diagnostics (www.ekfdiagnostics.com), the global in vitro diagnostics business, announces that its subsidiary company EKF Molecular Diagnostics is exhibiting its ground-breaking PointMan™ DNA-enrichment technology at Tri-Con 2014 in San Francisco, CA, Booth #417, 10-14th February.

PointMan is a real-time PCR technology that provides reliable and extremely sensitive detection of cancer-related mutations. Fully compatible with industry standard instruments and DNA extraction methods, it is highly specific and efficient in amplifying the target sequence, while simultaneously suppressing amplification of the wild-type.  The resulting sample is effectively enriched for the mutation, providing industry-leading sensitivity across a wide variety of sample types, including whole blood.

PointMan’s landmark ability to enrich low-level DNA mutations from whole blood is the focus of an ongoing collaboration between EKF Molecular Diagnostics and the Institute of Life Sciences at Swansea University. Recent preliminary results from a study of samples archived in the Wales Cancer Bank, have demonstrated that PointMan technology could enable non-invasive blood based testing and reduce the need for tumor biopsies for cancer patient mutation status assessment.

Personnel from EKF Molecular Diagnostics will be on hand at Tri-Con 2014 to demonstrate and discuss the effectiveness of EKF Molecular's portfolio of PointMan DNA enrichment kits that detect mutations for cancer biomarkers including: BRAF, KRAS, EGFR, NRAS and JAK2. These genes are associated with skin melanoma, colorectal and lung cancers, as well as myeloma.

The 21st International Molecular Medicine Tri-Conference will focus on Drug Discovery, Genomics, Diagnostics and Information Technology.  “Tri-Con 2014 provides an ideal platform to feature our growing range of products and technologies developed to meet an increasing demand for superior sensitivity and specificity in molecular diagnostics,” said Andrew Webb, CEO, EKF Molecular Diagnostics.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    EKF Diagnostics. (2014, August 15). EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014. News-Medical. Retrieved on May 21, 2019 from https://www.news-medical.net/news/20140211/EKF-Molecular-Diagnostics-to-exhibit-PointMan-DNA-enrichment-technology-at-Tri-Con-2014.aspx.

  • MLA

    EKF Diagnostics. "EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014". News-Medical. 21 May 2019. <https://www.news-medical.net/news/20140211/EKF-Molecular-Diagnostics-to-exhibit-PointMan-DNA-enrichment-technology-at-Tri-Con-2014.aspx>.

  • Chicago

    EKF Diagnostics. "EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014". News-Medical. https://www.news-medical.net/news/20140211/EKF-Molecular-Diagnostics-to-exhibit-PointMan-DNA-enrichment-technology-at-Tri-Con-2014.aspx. (accessed May 21, 2019).

  • Harvard

    EKF Diagnostics. 2014. EKF Molecular Diagnostics to exhibit PointMan DNA-enrichment technology at Tri-Con 2014. News-Medical, viewed 21 May 2019, https://www.news-medical.net/news/20140211/EKF-Molecular-Diagnostics-to-exhibit-PointMan-DNA-enrichment-technology-at-Tri-Con-2014.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
EKF Diagnostics issues new educational guide to ‘Diabetes and HbA1c testing’